Two opposed equally weighted beams with direction 0° and 180°, respectively. Isocentric technique. Field width 10 cm (both). Field length 12 cm (both). Two corners blocked in each beam. No wedges.
Simulator port films. Treatment verification films x 2. Measurement of entrance dose x 2. 56-year old female presented with a 2 cm x 1.5 cm hard, mobile lump in the upper outer quadrant of the left breast. There was no fixation to skin or underlying muscle, and no regional lymphadenopathy palpable. Mammography showed a mass suspicious of malignancy. Clinical diagnosis T1a NO MO carcinoma. Excision biopsy showed infiltrating ductal carcinoma. Wide local excision and axillary dissection was then performed. Histology showed complete excision of primary tumour and 12 axillary lymph nodes excised, all 12 free of metastases. Surgical clips were placed in the tumour bed at time ofre-excision. Radical radiotherapy after radical surgery. No systemic therapy. No GTV to be defined. CTV I : The local tumour bed with or without the use of surgical clips [C50.4-2]. CTV II : The entire breast (outside CTV I, see above) , the extent to be defined anatomically by palpation and CT scan [C50.9-2].
For CTV I : A 1 cm margin is added to allow for movements of the chest wall due to respiration, and variation in repositioning of the beams. . For CTV II: A 1 cm margin is added to allow for movements of the chest wall due to respiration, and variation in repositioning of the beams. (See Fig. 11 PTV I: 64 Gy in 32 fractions over 6.5 weeks. PTV II: 50 Gy in 25 fractions over 5 weeks.
A: 30 Gy in at most 200 cm 3 . B: 30 Gy in at most 30 cm 3 . C: Less than 5 Gy. PTV I: Two opposed tangential photon beams plus electron beam. PTV II: Two opposed tangential photon beams.
PTV I and II: Supine with arms raised above and immobilization of the head and on a wedge to make the sternum horizontal. Immobilized using plastic cast or arm poles and foot board.
PTV I AND II: Transverse section through the site of the excised tumor [24J.
Single plane dose calculation using photon beam generating functions with correction for oblique incidence and tissue inhomogeneity, but no correction for loss of sidescatter in 3-D. Electron beam calculation based on uncorrected isodose data.
PTV I: (a) Tangential photon beams as described for PTV II. the densely dotted area and PTV II by the sparsely dotted area. The dose specified for prescription and for recording of this part of the whole treatment is 50 Gy on the beam axes midway between the beam entrances, which also corresponds to the center of the PTV II.
Fig.II.2.h. Isodose values (relative values)
for the dose distribution with one 9 MeV electron beam for PTV I (indicated by densely dotted area). The dose specified for prescription and for recording of this part of the whole treatment is 100% (the beam energy chosen so that this value is found near the center of the PTV). The absolute dose value is 14 Gy. Fig. I1 .2.c. Isodose values (absolute values in Gy) for the total dose distribution. For reporting purposes, the following specification of dose and fractionation was adopted:
For PTV I the dose for reporting was specified at the center of PTV I = 64 Gy, with the variation 66-60 Gy, given in 32 fractions over 6.5 weeks.
For PTV II the dose only from the two photon beams, midway between the beam entrances was taken to be representative of the dose to the breast tissue outside the " boosted" volume (thus disregarding the electron treatment of PTV I). Total dose to PTV II is 50 Gy, with the variation 64-50 Gy, given in 25-32 fractions over 5-6.5 weeks. Radical radiotherapy to prostate gland and pelvic lymph nodes.
CONTROL
Tumour within the prostate gland.
CTV I: The entire prostate gland with good left lateral margin. Define by CT scan and palpation [C61.9) . CTV II: The regional lymph nodes in the obturator, internal and external iliac and pre-sacral lymph nodes and also common iliac lymph nodes [C77.5B-4, C77.5A-4, C77.5C) .
For CTV I and II to allow for variation in repositioning in the beams. There is little organ movement. (See Fig. 11 .3.) 1 3 Fig.II.3 .a. Isodose (absolute values) distribution for the first treatmen t of both PTV I and II (the latter indicated by the sparsely dotted area, and the former indicated by the densely dotted area). The dose specified for prescription and for recording (44 Gy) is at the intersection ofthe beams. For PTV I (the primary tumor and prostate) the dose at the intersection (see below) of the 7 beams and the variation of dose in PTV 1= 66 Gy (69-66) given in 32 fractions over 45 days. For PTV II (the regional lymph nodes) the dose at a point considered significant for the regional lymph nodes (indicated by the circle) = 65 Gy) , and the variation in dose in PTV II = 68 -52 Gy, given in 22-32 fractions over 31-45 days. Note: The example illustrates the problems encountered in "boost" therapy. It is usually only possible to achieve a homogeneous dose to PTV L It is recommended that a display of the total dose distribution from the combined treatments to both PTVs is made at the outset. Also, for this case, note that for the dose planning of the two different parts of the whole treatment, different sections were used, but for reporting purposes in this case, only one section was considered, disregarding the possible importance of 3-D evaluation. The true minimum dose ofPTV II will then be lower than the one stated above, and of the order 42 Gy at the most cranial section. 2. Maximum and minimum. PTV II: 1. A point is selected that is considered to be representative for the regional lymph nodes (ICRU Reference Point 2) 2. Maximum and minimum. 58-year old male presented with a 4.5 cm x 3.5 cm x 4.0 cm ulcerated tumor in the left floor of the mouth. The tumour extended into the tongue but did not reach the midline. It did not involve the submandibular salivary gland. There was no fixation to the mandible. There were no palpable regional lymph nodes. Physical examination otherwise unremarkable. Clinical stage = T4 NO MO . Biopsy showed moderately differentiated squamous cell carcinoma. The patient was considered unfit for radical surgery. CTV II: The ipsilateral regional lymph nodes in the submandibular region, the neck, and the supraclavicular fossa [C77.0C-2, C77.0E-2, C77.0F-2] .
ORGANS AT
1 cm margin is added to allow for movements and variation in beam set up. Note I: CTV I is well located inside CTV II and thus needs no special margin for planning purpose, since no external beam boost therapy was intended. Note II: Since the dose to the cord would have been unacceptable with the same margin around the CTVs in all direction, the compromise was made to retain the prescribed dose (see below) but accept a smaller positional margin close to the cord. Extra careful checking of the beam positioning close to the cord then becomes necessary. (See Fig. 11 Fig. II.4 .h. Dose distribution (relative values normalized to the specification dose, the 85%, 95%, 100%, and 105% being shown in the graphs) in section #I, at the level of the GTV. This level was considered to be the most relevant for dose specification rather than level #II (which is the level of the intersection of the central rays, but where there is no GTV). Thus, an ICRU Specification Point 2 was defined in section #I centrally in the GTV (indicated by the filled squa re). The dose prescribed at this Reference Point 2 is 100% = 66 Gy. Simulator port films. Verification films of photon beams three times a week (with special attention to the medial borders, see above). Diode measurements of entrance dose x 2.
RIG HT
1. Centrally in PTV in section # I (ICRU Reference Point 2) (since the beams intersect at the level of section # II where there is only subclinical disease, and furthermore, they do not intersect well within the tissues of the patient) = 66 Gy. 2. Maximum and minimum doses in PTV (to be found in sections #11 and III, respectively) = 108% (71 Gy) and 84% (=55 Gy), respectively. Note that the minimum dose can be raised by using beam compensating filters, bolus to diminish the effect of build· up, or additional treatment to section #111. 3. Furthermore, the following dose parameters to the PTV are available:
-average value = 102% (standard deviation = 6.6).
median value = 101%, 4. Organs at risk:
Spinal cord dose = maximum 50% = 33 Gy.
Dose to the right parotid gland = < 15% = < 10 Gy. 
DOSE SPECIFICATION FOR REPORTING
A 38-year old male presented with a painless mass in the right posterior thigh. Clinical and radiological examination indicated a liposarcoma in the long head of the biceps femoris muscle, which was verified by means of fine needle aspiration biopsy. At subsequent operation, the lateral part of the tumor was found to protrude out of the muscle. Microscopically, a grade IV liposarcoma was diagnosed, and the surgical margin was classified as probably not radical. Thus postoperative radiotherapy was indicated.
Radical radiotherapy to avoid local recurrence.
Not to be defined, since there was no demonstrable tumor left after surgery.
Posterior compartment of the right thigh [C49.2B-1J.
To allow for variations in set-up; organ movement is negligible. (See Fig. 11 .5)
The testes were carefully pushed well outside the beams [C62.9-4J. 
Sciatic nerve

Excision border
Muscle fascia Fig. 1I .5.b. At OIX'ration. the medial part of the tumor was found embedded in the long head of the bieeps muscle. The lateral part of the tumor protruded out of the muscle and was oovered by a thin membrane. Whether this was muscle fascia or a tumor pseudocapsule was uncertain. The tumor and the long muscle head were removed en bloc. Microscopic examination showed a grad", IV liposarcoma. There Wall no fascialoontainment of the tumor in the lateral part. The margin was thus c1llSfiified as marginal, and radiotherapy was indicated. Fig. 11 .5.c. The most proximal and distal sections are shown with a groy scale. The femur is displayed as a solid structure (white) as well as the grOl!S tumor (pink), while the biceps muscle is displayed as a semitransparent structure (magenta). The spatial relationship of these structures can ellllily be oonceived. The orientation of the image is given by the patient related coordinate sysl<)m (L '" Left. Fig. 11 .5.e. Transverse section through theoontral part of the PTV. The entire cross· section of the posterior compartment was defined as the CTV. Radiation is given by two oppoaing beams. beam directions 90' and 270' . respectively. Irradiation of the entire cross·section of the thigh is l\Voided. The numbers indicate absolute dose levels (Gy l for the individual isodose curves. The specified target dose (P'rV-doscl is 51 Gy at a point centrally in the PTV 1_). This point was chosen as being more representative than the point midway on the beam axes (. ). The maximum dose to the P1'V is 53 Gy, and the minimum dose is 45Gy. Fig. II .5.f. Thegeomelric limitsofthe two beams aredisplayed in green (beam III I and rod (beam 112). Sagittal section through the femur constructed from 55 trunsverse CT·sections, of which three are IIhown here 
